Drug intelligence / Profile preview

RO7123520

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous

Overview

RO7123520 is a small molecule drug developed by Hoffmann-La Roche for the adjunctive treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to standard-of-care therapies, including methotrexate and anti-TNF-alpha agents. The drug was evaluated in Phase IIa/b clinical trials as an intravenous therapy. Its mechanism of action is described as a TNF blocker, though the precise molecular target has not been fully disclosed. Development for rheumatoid arthritis was discontinued after Phase II trials[1][2][3][4][6].

Other names: anti-cadherin-11 monoclonal antibodyanti-cadherin11 monoclonal antibodyanti-cadherin 11 monoclonal antibodyanti-tnf-alpha-Hoffmann-La Roche-rheumatoid arthritis

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on RO7123520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7123520.

Explore the full profile